{
  "combination": {
    "prompt": "direct_mcode_evidence_based_concise",
    "model": "deepseek-chat"
  },
  "success": true,
  "cv_average_score": 1.0,
  "cv_std_score": 0.0,
  "fold_scores": [
    1.0,
    1.0,
    1.0,
    1.0,
    1.0
  ],
  "cv_folds": 3,
  "total_trials": 5,
  "total_elements": 124,
  "errors": [],
  "timestamp": "2025-09-19T10:15:27.083173",
  "metrics": {
    "precision": 1.0,
    "recall": 1.0,
    "f1_score": 1.0
  },
  "predicted_mcode": [
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Locally advanced breast carcinoma",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Histologically confirmed locally advanced breast carcinoma"
    },
    {
      "element_type": "TNMStage",
      "code": "444148008",
      "display": "T3 stage of breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage T3 T4, N2 or N3 disease"
    },
    {
      "element_type": "TNMStage",
      "code": "444149000",
      "display": "T4 stage of breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage T3 T4, N2 or N3 disease"
    },
    {
      "element_type": "TNMStage",
      "code": "444152008",
      "display": "N2 stage of breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage T3 T4, N2 or N3 disease"
    },
    {
      "element_type": "TNMStage",
      "code": "444153003",
      "display": "N3 stage of breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage T3 T4, N2 or N3 disease"
    },
    {
      "element_type": "Patient",
      "code": "184099003",
      "display": "Age 18 years or older",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Age: 18 and over"
    },
    {
      "element_type": "Patient",
      "code": "248153007",
      "display": "Male",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Sex: Male or female"
    },
    {
      "element_type": "Patient",
      "code": "248152002",
      "display": "Female",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Sex: Male or female"
    },
    {
      "element_type": "Patient",
      "code": "271872005",
      "display": "Karnofsky performance status scale score",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Performance status: Karnofsky 80-100%"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Locally advanced breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "patients with locally advanced breast cancer who will undergo chemotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "367336001",
      "display": "Chemotherapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "patients with locally advanced breast cancer who will undergo chemotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108290001",
      "display": "Radiation therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "the patient may be offered radiation therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "396232000",
      "display": "Surgical resection",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "the patient is evaluated for surgical resection of the tumor"
    },
    {
      "element_type": "CancerTreatment",
      "code": "127788006",
      "display": "Positron emission tomography",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "127788006",
      "display": "Positron emission tomography",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Locally advanced breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients With Locally Advanced Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Advanced breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage IV Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Recurrent Breast Carcinoma"
    },
    {
      "element_type": "TNMStage",
      "code": "399537006",
      "display": "Stage IV breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage IV Breast Cancer"
    },
    {
      "element_type": "CancerBiomarker",
      "code": "706897003",
      "display": "HER2/neu receptor positive",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER2/Neu Positive"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "HER2 positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with stage IV HER2+ breast cancer treated to: No evidence of disease (NED), or Stable bone only disease after definitive therapy"
    },
    {
      "element_type": "TNMStage",
      "code": "444148008",
      "display": "Stage IV breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with stage IV HER2+ breast cancer treated to: No evidence of disease (NED), or Stable bone only disease after definitive therapy"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "HER2 positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in the primary tumor or metastasis; or documented gene amplification by fluorescent in situ hybridization (FISH) analysis"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387126007",
      "display": "Trastuzumab therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy, or trastuzumab and pertuzumab combination therapy administered per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "713575000",
      "display": "Pertuzumab therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy, or trastuzumab and pertuzumab combination therapy administered per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108290001",
      "display": "Bisphosphonate therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients on bisphosphonates and/or endocrine therapy are eligible"
    },
    {
      "element_type": "CancerTreatment",
      "code": "373871005",
      "display": "Endocrine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients on bisphosphonates and/or endocrine therapy are eligible"
    },
    {
      "element_type": "PatientDemographics",
      "code": "424144002",
      "display": "Age 18 years or older",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "minimumAge: 18 Years"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Stage IV breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "432969001",
      "display": "HER2 positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "386872004",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "trastuzumab (or trastuzumab and pertuzumab) per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "443263003",
      "display": "Pertuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "trastuzumab (or trastuzumab and pertuzumab) per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703003",
      "display": "Vaccine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "vaccine therapy with or without polysaccharide-K"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703003",
      "display": "HER2 ICD peptide-based vaccine",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients receive HER2 ICD peptide-based vaccine intradermally (ID) once monthly for 3 months"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703003",
      "display": "Polysaccharide-K",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "polysaccharide-K PO BID for 4 months"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Stage IV breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage IV HER2 Positive Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "702971005",
      "display": "HER2 positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage IV HER2 Positive Breast Cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703005",
      "display": "Vaccine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Vaccine Therapy With or Without Polysaccharide-K"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703005",
      "display": "HER2 ICD peptide-based vaccine",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER2 ICD Peptide-Based Vaccine"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703005",
      "display": "HER2-targeted monoclonal antibody therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER2-Targeted Monoclonal Antibody Therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703005",
      "display": "Combination immunotherapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®)"
    },
    {
      "element_type": "PatientDemographics",
      "code": "424144002",
      "display": "Age",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "\"Age, Continuous\" with median values of 52 years (range 36-62) for Arm I and 59 years (range 33-75) for Arm II"
    },
    {
      "element_type": "PatientDemographics",
      "code": "703118005",
      "display": "Female sex",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "\"Sex: Female, Male\" with 16 female participants in Arm I, 15 female participants in Arm II, and 0 male participants in both arms"
    },
    {
      "element_type": "PatientDemographics",
      "code": "703117000",
      "display": "Male sex",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "\"Sex: Female, Male\" with 0 male participants in Arm I, 0 male participants in Arm II, and 0 male participants in Total"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387007008",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "\"Trastuzumab: Given per standard of care\" in both Arm I and Arm II treatment regimens"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703005",
      "display": "Pertuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "\"Pertuzumab: Given per standard of care\" in both Arm I and Arm II treatment regimens"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703005",
      "display": "HER2 ICD peptide-based vaccine",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "\"HER2 ICD peptide-based vaccine ID once monthly for 3 months\" administered to patients in both treatment arms"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "trastuzumab (or trastuzumab and pertuzumab) per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "trastuzumab (or trastuzumab and pertuzumab) as in Arm I"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763875007",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Trastuzumab: Given per standard of care"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Early-stage Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Invasive breast carcinoma",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with histologically confirmed HR+/HER2- invasive breast cancer that is sensitive to endocrine therapy."
    },
    {
      "element_type": "CancerCondition",
      "code": "432519008",
      "display": "Hormone receptor positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with histologically confirmed HR+/HER2- invasive breast cancer that is sensitive to endocrine therapy."
    },
    {
      "element_type": "CancerCondition",
      "code": "703548004",
      "display": "HER2 negative breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with histologically confirmed HR+/HER2- invasive breast cancer that is sensitive to endocrine therapy."
    },
    {
      "element_type": "TNMStage",
      "code": "444256004",
      "display": "T2N1M0 stage breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Tumor diameter >2 cm, clinically positive axillary lymph nodes not more than 2 (T2N1M0)"
    },
    {
      "element_type": "Patient",
      "code": "248152002",
      "display": "Female",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Females aged 18 to 70 years"
    },
    {
      "element_type": "Patient",
      "code": "424144002",
      "display": "Age 18 years",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "minimumAge: 18 Years"
    },
    {
      "element_type": "Patient",
      "code": "103330006",
      "display": "Age 70 years",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "maximumAge: 70 Years"
    },
    {
      "element_type": "CancerCondition",
      "code": "399068003",
      "display": "Metastatic breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Metastatic breast cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Hormone receptor positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "operable hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Hormone receptor positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "early-stage HR+/HER2- breast cancer patients"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Hormone receptor positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "ER+/HER2- early invasive breast cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Hormone receptor positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HR+/HER2- breast cancer with high recurrence risk and insensitivity to endocrine therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763076005",
      "display": "CDK4/6 inhibitor therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "evaluate the efficacy of neoadjuvant CDK4/6 inhibitors in patients with high-risk EPclin multigene risk analysis"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763076005",
      "display": "CDK4/6 inhibitor therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "explore predictive biomarkers for sensitivity to CDK4/6 inhibitor therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763076005",
      "display": "CDK4/6 inhibitor therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "the combination of palbociclib and letrozole significantly inhibited Ki-67 expression"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763076005",
      "display": "CDK4/6 inhibitor therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "a regimen containing abemaciclib is significantly superior to anastrozole monotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763076005",
      "display": "CDK4/6 inhibitor therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "neoadjuvant endocrine therapy with palbociclib or ribociclib is comparable in efficacy to neoadjuvant chemotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763076005",
      "display": "CDK4/6 inhibitor therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "treated with or without CDK4/6 inhibitors"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HR+/HER2- Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "432969002",
      "display": "Hormone receptor positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HR+/HER2- Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "432969002",
      "display": "HER2 negative breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HR+/HER2- Breast Cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763158003",
      "display": "Endocrine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Neoadjuvant Endocrine Therapy Treatment"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763158003",
      "display": "Neoadjuvant endocrine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Neoadjuvant Endocrine Therapy Treatment"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763158003",
      "display": "CDK4/6 inhibitors",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "CDK4/6 Inhibitors"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Breast Neoplasms"
    },
    {
      "element_type": "CancerCondition",
      "code": "92564006",
      "display": "Ductal carcinoma of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Carcinoma, Ductal, Breast"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Breast carcinoma",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Females with a history of T2N0M0 breast carcinoma (tumor ≤3 cm in largest dimension)"
    },
    {
      "element_type": "TNMStage",
      "code": "444256004",
      "display": "T2N0M0 stage breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Females with a history of T2N0M0 breast carcinoma (tumor ≤3 cm in largest dimension)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "236970008",
      "display": "Segmental mastectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "236970008",
      "display": "Lumpectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108290001",
      "display": "Breast conservation therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Objective signs of mild breast damage post Breast Conservation Therapy"
    },
    {
      "element_type": "Patient",
      "code": "248152002",
      "display": "Female",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Females with a history of T2N0M0 breast carcinoma"
    },
    {
      "element_type": "Patient",
      "code": "424144002",
      "display": "Current chronological age (observable entity)",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "minimumAge: 18 Years maximumAge: 75 Years"
    },
    {
      "element_type": "CancerTreatment",
      "code": "443885006",
      "display": "Autologous fat transplantation",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "transplantation of autologous fat augmented with Adipose Derived Regenerative Cells (ADRCs)"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.8,
      "evidence_text": "patients with functional and cosmetic breast deformities post segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "396232000",
      "display": "Mastectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "post segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "396232000",
      "display": "Lumpectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "breast deformities post segmental breast resection (lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "443497002",
      "display": "Excision of breast tissue",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "segmental breast resection (lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "169317007",
      "display": "Radiotherapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "with or without radiation therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "713295002",
      "display": "Autologous fat grafting",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "autologous fat enhanced w/ regenerative cells transplanted to reconstruct breast deformities"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Breast Neoplasms"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Adenocarcinoma of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Unilateral, operable, histologically confirmed adenocarcinoma of the breast"
    },
    {
      "element_type": "CancerCondition",
      "code": "444055006",
      "display": "Estrogen receptor positive malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "432519008",
      "display": "HER2 negative breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by chemotherapy"
    },
    {
      "element_type": "CancerCondition",
      "code": "722713004",
      "display": "Triple negative breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER-2 positive (IHC 3+ OR FISH+) and or triple-negative breast cancer"
    },
    {
      "element_type": "TNMStage",
      "code": "444256004",
      "display": "Stage I breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage I-III"
    },
    {
      "element_type": "TNMStage",
      "code": "444258003",
      "display": "Stage II breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage I-III"
    },
    {
      "element_type": "TNMStage",
      "code": "444259006",
      "display": "Stage III breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage I-III"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108290001",
      "display": "Surgical procedure",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Primary surgery with clear margins plus axillary dissection"
    },
    {
      "element_type": "CancerTreatment",
      "code": "367336001",
      "display": "Chemotherapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "Able to start protocol Rx within 8 weeks of surgery"
    },
    {
      "element_type": "Patient",
      "code": "248152002",
      "display": "Female",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Female patients, age 18~40"
    },
    {
      "element_type": "Patient",
      "code": "424144002",
      "display": "Current chronological age (observable entity)",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "minimumAge: 18 Years"
    },
    {
      "element_type": "Patient",
      "code": "424144002",
      "display": "Current chronological age (observable entity)",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "maximumAge: 40 Years"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "young breast cancer patients"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387608007",
      "display": "Paclitaxel",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "strategies incorporating paclitaxel"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387608007",
      "display": "Paclitaxel",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "incorporating paclitaxel to anthracycline-based regimens"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387608007",
      "display": "Paclitaxel",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "evaluate the efficacy and safety of different strategies incorporating paclitaxel"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Adjuvant Therapy for Operable Breast Cancer Patients"
    },
    {
      "element_type": "PatientDemographics",
      "code": "424144002",
      "display": "Current chronological age (observable entity)",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients Less Than 40 Years Old"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108981000",
      "display": "Epirubicin (substance)",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "EC-wP versus EP-wP as Adjuvant Therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387458008",
      "display": "Cyclophosphamide (substance)",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "EC-wP versus EP-wP as Adjuvant Therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387127001",
      "display": "Paclitaxel (substance)",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "EC-wP versus EP-wP as Adjuvant Therapy"
    }
  ]
}